69
Participants
Start Date
April 30, 2010
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
Placebo
An infusion of an identically appearing solution of sugar water will be intravenously administered.
Strata 1 CXL-1020
Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
Strata 2 CXL-1020
One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
Strata 3 CXL-1020
A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
Montefiore Medical Center, The Bronx
University of Maryland Medical Center, Baltimore
Wake Forest University Health Sciences, Winston-Salem
Medical University of South Carolina, Charleston
University of Florida, Jacksonville
University of Florida, Gainesville
Florida Hospital Transplant Center, Orlando
Stern Cardiovascular Center PA, Germantown
Davis Heart & Lung Research Institute, Columbus
University Hospitals Case Medical Center, Cleveland
University of Cincinnati, Cincinnati
DMC Cardiovascular Institute, Detroit
Henry Ford Health System, Detroit
Ochsner Clinic Foundation, New Orleans
University of Medicine & Dentistry of New Jersey - New Jersey Medical School, South Orange
Lead Sponsor
Collaborators (1)
Cardioxyl Pharmaceuticals, Inc
INDUSTRY
Bristol-Myers Squibb
INDUSTRY